CN101821267B - 用于治疗丙型肝炎的化合物 - Google Patents
用于治疗丙型肝炎的化合物 Download PDFInfo
- Publication number
- CN101821267B CN101821267B CN2008801108622A CN200880110862A CN101821267B CN 101821267 B CN101821267 B CN 101821267B CN 2008801108622 A CN2008801108622 A CN 2008801108622A CN 200880110862 A CN200880110862 A CN 200880110862A CN 101821267 B CN101821267 B CN 101821267B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cyclohexyl
- mmol
- methoxy
- indolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1c(CN(*)I)cccc1 Chemical compound *c1c(CN(*)I)cccc1 0.000 description 9
- DVOURNSDTUALLG-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(OC)=O)c(C(F)(F)F)n[n]4C)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(OC)=O)c(C(F)(F)F)n[n]4C)=Cc4c-2ccc(OC)c4)c3c1)=O DVOURNSDTUALLG-UHFFFAOYSA-N 0.000 description 1
- TVSJKFMGKJGPMI-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(OC)=O)c(C)n[n]4C)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(OC)=O)c(C)n[n]4C)=Cc4c-2ccc(OC)c4)c3c1)=O TVSJKFMGKJGPMI-UHFFFAOYSA-N 0.000 description 1
- HQVUPUXEYZGZCV-UKRDSVFVSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(/C(/N(C(C)C)N)=C(/C=[IH])\C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(/C(/N(C(C)C)N)=C(/C=[IH])\C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O HQVUPUXEYZGZCV-UKRDSVFVSA-N 0.000 description 1
- SCJDMZMBLFJDJQ-UHFFFAOYSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N(CCC4)CC4N(C)C)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N(CCC4)CC4N(C)C)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O SCJDMZMBLFJDJQ-UHFFFAOYSA-N 0.000 description 1
- DOARTRHAJHRUGC-HKBQPEDESA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N4C[C@@H](COC)OCC4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N4C[C@@H](COC)OCC4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O DOARTRHAJHRUGC-HKBQPEDESA-N 0.000 description 1
- CHTASSIVQNHABB-NOCOOEENSA-N CC(C)N[C@H](C)/C(/C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O)=C(\C=N)/C(N1CC(COC)OCC1)=O Chemical compound CC(C)N[C@H](C)/C(/C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O)=C(\C=N)/C(N1CC(COC)OCC1)=O CHTASSIVQNHABB-NOCOOEENSA-N 0.000 description 1
- RWAARBSUQRQMCG-HNRBIFIRSA-N CC(C)S(NC(c(cc1)cc2c1c(C1CCCCC1)c-1[n]2CC(c([n](C(C)(C)C)nc2)c2C(N2C[C@H](C)N(C)[C@H](C)C2)=O)=Cc2c-1ccc(OC)c2)=O)(=O)=O Chemical compound CC(C)S(NC(c(cc1)cc2c1c(C1CCCCC1)c-1[n]2CC(c([n](C(C)(C)C)nc2)c2C(N2C[C@H](C)N(C)[C@H](C)C2)=O)=Cc2c-1ccc(OC)c2)=O)(=O)=O RWAARBSUQRQMCG-HNRBIFIRSA-N 0.000 description 1
- SHGWZNXCBPHSLJ-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N4CC(CC5)OC5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C)nc4)c4C(N4CC(CC5)OC5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O SHGWZNXCBPHSLJ-UHFFFAOYSA-N 0.000 description 1
- RTKINLUTMMKSCT-UHFFFAOYSA-N CC(C)[n]1nc(C)c(C(OC)=O)c1C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(C(C)C)(=O)=O)=O)c3)c3[n]2C1 Chemical compound CC(C)[n]1nc(C)c(C(OC)=O)c1C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(C(C)C)(=O)=O)=O)c3)c3[n]2C1 RTKINLUTMMKSCT-UHFFFAOYSA-N 0.000 description 1
- LUEZAJMCGIDCEZ-UHFFFAOYSA-N CC(C)[n]1ncc(C(N2C3CN(C)CC2C3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3/C(/NS(C(C)C)(=O)=O)=[O]\C Chemical compound CC(C)[n]1ncc(C(N2C3CN(C)CC2C3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3/C(/NS(C(C)C)(=O)=O)=[O]\C LUEZAJMCGIDCEZ-UHFFFAOYSA-N 0.000 description 1
- XQCYCFCSRRSBRG-UHFFFAOYSA-N CC(C)[n]1ncc(C(N2C3COCC2COC3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O Chemical compound CC(C)[n]1ncc(C(N2C3COCC2COC3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O XQCYCFCSRRSBRG-UHFFFAOYSA-N 0.000 description 1
- AIILMRNXXZTNHA-HNRBIFIRSA-N CC(C)[n]1ncc(C(N2C[C@H](C)N(C)[C@H](C)C2)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O Chemical compound CC(C)[n]1ncc(C(N2C[C@H](C)N(C)[C@H](C)C2)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O AIILMRNXXZTNHA-HNRBIFIRSA-N 0.000 description 1
- MPOBLKJBZIYFOQ-UHFFFAOYSA-N CCC(C)S(NC(c1ccc(C(C)(C2N3CC(c([n](C)nc4)c4C(N(CCC4)CC4N(C)C)=O)=Cc4c2ccc(OC)c4)C2CCCCC2)c3c1)=O)(=O)=O Chemical compound CCC(C)S(NC(c1ccc(C(C)(C2N3CC(c([n](C)nc4)c4C(N(CCC4)CC4N(C)C)=O)=Cc4c2ccc(OC)c4)C2CCCCC2)c3c1)=O)(=O)=O MPOBLKJBZIYFOQ-UHFFFAOYSA-N 0.000 description 1
- SPIAFSLZSYHZHG-NXMIGULDSA-N CCC(C)c1c(-c(ccc(OC)c2)c2C=C(C2)c([n](C)nc3)c3C(N3C[C@H](C)N(C)[C@H](C)C3)=O)[n]2c2cc(C(NS(CC(C)C)(=O)=O)=O)ccc12 Chemical compound CCC(C)c1c(-c(ccc(OC)c2)c2C=C(C2)c([n](C)nc3)c3C(N3C[C@H](C)N(C)[C@H](C)C3)=O)[n]2c2cc(C(NS(CC(C)C)(=O)=O)=O)ccc12 SPIAFSLZSYHZHG-NXMIGULDSA-N 0.000 description 1
- IYNAAFSYIQLUHN-UHFFFAOYSA-N CCN(CC[U])C(c1c(C(C[n]2c3c4)=Cc(cc(cc5)[O](C)C)c5-c2c(C2CCCCC2)c3ccc4C(OC(C)(C)C)=O)[o]cn1)=O Chemical compound CCN(CC[U])C(c1c(C(C[n]2c3c4)=Cc(cc(cc5)[O](C)C)c5-c2c(C2CCCCC2)c3ccc4C(OC(C)(C)C)=O)[o]cn1)=O IYNAAFSYIQLUHN-UHFFFAOYSA-N 0.000 description 1
- JMJRUKHJNKPIKV-UHFFFAOYSA-N CCOC(c1c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(O)=O)[n](C(C)(C)C)nc1)=O Chemical compound CCOC(c1c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(O)=O)[n](C(C)(C)C)nc1)=O JMJRUKHJNKPIKV-UHFFFAOYSA-N 0.000 description 1
- ZEZAIOZYAYCXEN-UHFFFAOYSA-N CCOC(c1c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(OC(C)(C)C)=O)[n](CC(F)(F)F)nc1)=O Chemical compound CCOC(c1c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(OC(C)(C)C)=O)[n](CC(F)(F)F)nc1)=O ZEZAIOZYAYCXEN-UHFFFAOYSA-N 0.000 description 1
- GJZBWFQUDWYBCZ-UHFFFAOYSA-N CCOC(c1c[n](C)nc1C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N(C)C)(=O)=O)=O)c3)c3[n]2C1)=O Chemical compound CCOC(c1c[n](C)nc1C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N(C)C)(=O)=O)=O)c3)c3[n]2C1)=O GJZBWFQUDWYBCZ-UHFFFAOYSA-N 0.000 description 1
- IMJLSIFICORSAE-HKBQPEDESA-N C[n]1ncc(C(N2C[C@@H](COC)OCC2)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(N1CCOCC1)(=O)=O)=O Chemical compound C[n]1ncc(C(N2C[C@@H](COC)OCC2)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(N1CCOCC1)(=O)=O)=O IMJLSIFICORSAE-HKBQPEDESA-N 0.000 description 1
- MOALNACHYWYZJR-RNPORBBMSA-N C[n]1ncc(C(N2[C@@H]3C#C[C@H]2CC3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(N1CCOCC1)(=O)=O)=O Chemical compound C[n]1ncc(C(N2[C@@H]3C#C[C@H]2CC3)=O)c1C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(N1CCOCC1)(=O)=O)=O MOALNACHYWYZJR-RNPORBBMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95481407P | 2007-08-09 | 2007-08-09 | |
| US60/954,814 | 2007-08-09 | ||
| US4994408P | 2008-05-02 | 2008-05-02 | |
| US61/049,944 | 2008-05-02 | ||
| US12/180,994 US7652004B2 (en) | 2007-08-09 | 2008-07-28 | Compounds for the treatment of hepatitis C |
| US12/180,994 | 2008-07-28 | ||
| PCT/US2008/071881 WO2009029384A2 (en) | 2007-08-09 | 2008-08-01 | Compounds for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101821267A CN101821267A (zh) | 2010-09-01 |
| CN101821267B true CN101821267B (zh) | 2013-07-10 |
Family
ID=40261456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801108622A Expired - Fee Related CN101821267B (zh) | 2007-08-09 | 2008-08-01 | 用于治疗丙型肝炎的化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7652004B2 (https=) |
| EP (1) | EP2183252B1 (https=) |
| JP (1) | JP5465670B2 (https=) |
| KR (1) | KR20100066492A (https=) |
| CN (1) | CN101821267B (https=) |
| AR (1) | AR067897A1 (https=) |
| AU (1) | AU2008293845B2 (https=) |
| BR (1) | BRPI0814931A2 (https=) |
| CA (1) | CA2695781A1 (https=) |
| CL (1) | CL2008002353A1 (https=) |
| CO (1) | CO6251359A2 (https=) |
| EA (1) | EA015978B1 (https=) |
| MX (1) | MX2010001416A (https=) |
| NZ (1) | NZ583149A (https=) |
| PE (1) | PE20090618A1 (https=) |
| TW (1) | TW200906418A (https=) |
| WO (1) | WO2009029384A2 (https=) |
| ZA (1) | ZA201000923B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| KR20100108341A (ko) * | 2007-11-20 | 2010-10-06 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| KR20100124848A (ko) | 2008-03-27 | 2010-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| JP2012517468A (ja) * | 2009-02-11 | 2012-08-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎治療のための化合物 |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| CH706864B1 (de) | 2011-06-22 | 2016-03-31 | Central Glass Co Ltd | Verfahren zur Herstellung einer Pyrazol-Verbindung. |
| JP5915004B2 (ja) * | 2011-06-22 | 2016-05-11 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| EP3091022A3 (en) * | 2012-07-18 | 2016-12-14 | Bristol-Myers Squibb Holdings Ireland | Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1807403A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| JP5205370B2 (ja) * | 2006-05-25 | 2013-06-05 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| WO2007140200A2 (en) * | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2008
- 2008-07-28 US US12/180,994 patent/US7652004B2/en active Active
- 2008-08-01 MX MX2010001416A patent/MX2010001416A/es active IP Right Grant
- 2008-08-01 EP EP08828571.3A patent/EP2183252B1/en not_active Not-in-force
- 2008-08-01 JP JP2010520215A patent/JP5465670B2/ja not_active Expired - Fee Related
- 2008-08-01 BR BRPI0814931-3A2A patent/BRPI0814931A2/pt not_active IP Right Cessation
- 2008-08-01 CN CN2008801108622A patent/CN101821267B/zh not_active Expired - Fee Related
- 2008-08-01 CA CA2695781A patent/CA2695781A1/en not_active Abandoned
- 2008-08-01 AU AU2008293845A patent/AU2008293845B2/en not_active Ceased
- 2008-08-01 EA EA201000277A patent/EA015978B1/ru not_active IP Right Cessation
- 2008-08-01 KR KR1020107005086A patent/KR20100066492A/ko not_active Withdrawn
- 2008-08-01 NZ NZ583149A patent/NZ583149A/en not_active IP Right Cessation
- 2008-08-01 WO PCT/US2008/071881 patent/WO2009029384A2/en not_active Ceased
- 2008-08-08 TW TW097130410A patent/TW200906418A/zh unknown
- 2008-08-08 PE PE2008001327A patent/PE20090618A1/es not_active Application Discontinuation
- 2008-08-08 CL CL200802353A patent/CL2008002353A1/es unknown
- 2008-08-08 AR ARP080103488A patent/AR067897A1/es unknown
-
2010
- 2010-02-03 CO CO10011252A patent/CO6251359A2/es not_active Application Discontinuation
- 2010-02-08 ZA ZA2010/00923A patent/ZA201000923B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Kazutaka Ikegashira, et al..Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors.《Journal of Medicinal Chemistry》.2006,第49卷(第24期),6950-6953. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US7652004B2 (en) | 2010-01-26 |
| AR067897A1 (es) | 2009-10-28 |
| AU2008293845B2 (en) | 2013-02-14 |
| AU2008293845A1 (en) | 2009-03-05 |
| MX2010001416A (es) | 2010-03-01 |
| EA015978B1 (ru) | 2012-01-30 |
| CO6251359A2 (es) | 2011-02-21 |
| US20090074715A1 (en) | 2009-03-19 |
| WO2009029384A2 (en) | 2009-03-05 |
| JP2010535787A (ja) | 2010-11-25 |
| ZA201000923B (en) | 2011-04-28 |
| EP2183252A2 (en) | 2010-05-12 |
| EA201000277A1 (ru) | 2010-06-30 |
| PE20090618A1 (es) | 2009-05-16 |
| KR20100066492A (ko) | 2010-06-17 |
| WO2009029384A3 (en) | 2009-05-28 |
| EP2183252B1 (en) | 2015-01-14 |
| JP5465670B2 (ja) | 2014-04-09 |
| CL2008002353A1 (es) | 2008-10-24 |
| NZ583149A (en) | 2011-07-29 |
| CA2695781A1 (en) | 2009-03-05 |
| TW200906418A (en) | 2009-02-16 |
| CN101821267A (zh) | 2010-09-01 |
| BRPI0814931A2 (pt) | 2015-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101821267B (zh) | 用于治疗丙型肝炎的化合物 | |
| AU2007211988B2 (en) | HCV NS5B inhibitors | |
| CN109195965B (zh) | Wdr5蛋白质-蛋白质结合的抑制剂 | |
| CN101730698B (zh) | 用于治疗丙型肝炎的化合物 | |
| US7485633B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| CN101821268B (zh) | 用于治疗丙型肝炎的四环化合物 | |
| CN101679441B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101918410B (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| JP2010521483A (ja) | シクロプロピル縮合インドロベンゾアゼピンｈｃｖインヒビター | |
| CN104470925A (zh) | 作为激酶抑制剂的咪唑并三嗪甲腈 | |
| EP2280975B1 (en) | 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c | |
| CN101679437B (zh) | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| US8143243B2 (en) | Compounds for the treatment of hepatitis C | |
| EP2396329B1 (en) | Compounds for the treatment of hepatitis c | |
| CN101443336B (zh) | 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130710 Termination date: 20150801 |
|
| EXPY | Termination of patent right or utility model |